PTEN is an unreliable indicator of mTOR kinase inhbitor activity

Researchers from the Mayo clinic have foung that PTEN is not a reliable marker of mTOR kinase inhibitor sensitivity in glioblastoma multiforme xenografts treated with RAD001 (everolimus).

Axelar commence Phase I/II trial of IGF-1R inhibitor AXL-1717

Axelar have initiated a phase I/II clinical trial of its IGF-1R inhibitor AXL1717 in cancer patients.

Novartis plan to file RAD001 (everolimus) for metastatic kidney cancer by July

Novartis have accelerated its filing schedule for mTOR kinase inhibitor RAD001 (everolimus) after Phase III data showed the drug to double progression-free survival in metastatic kidney cancer. Novartis expect to file its submission by July and aim for a 2009 launch.

Boehringer Ingelheims BIBF-1120 shows efficacy in vivo

Boehringer Ingelheims VEGFR/PDGFR/FGFR kinase inhbitor BIBF-1120 has been shown to demonstrate anti-angiogenic properties in vivo in mouse xenograft and syngeneic rat tumor models. Magnetic resonance imaging shows the drug to reduce blood vessel density and integrity.

Oncothyreon initiate Phase I trial of PI3K inhibitor PX-866 for solid tumors

Oncothyreon have initiated the first Phase I trial of phosphatidylinositol 3 kinase (PI3K) inhbitor PX-866 in patients with advanced solid tumors.

Abbott publish series of multikinase inhibitors

Abbott have published a series of 7-Aminopyrazolo[1,5-a]pyrimidine urea receptor tyrosine kinase inhibitors that inhibit a variety of kinases including VEGFR, PDGFR, and KDR